Physician profile
Mark D Carlson
NPI 1144347568
$1,876.34
in general payments reported to CMS, 2019-2025
36 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $57.58 · 2021: $135 · 2022: $297 · 2023: $290 · 2024: $500 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.54 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $216.86 | 2019-2025 | Veozah |
| Astellas Pharma Global Development | $122.06 | 2024 | Veozah |
| Boston Scientific Corporation | $119.69 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.42 | 2019-2024 | |
| Daiichi Sankyo INC. | $70.83 | 2019-2024 | Injectafer |
| Ethicon US, LLC | $64.73 | 2021 | |
| Intuitive Surgical, INC. | $55.43 | 2024 | |
| Coopersurgical, INC. | $54.53 | 2023-2024 | Advincula Delineator Uterine Manipulator, Paragard T 380a |
| Conmed Corporation | $51.60 | 2024-2025 | Airseal |
| Allergan, INC. | $49.48 | 2019 | |
| Medicem INC. | $45.89 | 2024 | |
| Novo Nordisk INC | $44.41 | 2019-2025 | Ozempic |
| Amgen INC. | $43.28 | 2022-2023 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $42.09 | 2024 | Myfembree |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.47 | 2021-2023 | |
| Evofem Biosciences, INC. | $34.72 | 2022 | |
| Therapeuticsmd, INC. | $34.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $30.28 | 2021-2024 | Gardasil 9, Gardasil |
| Medtronic, INC. | $29.41 | 2024 | V-Loc 180 |
| Gilead Sciences, INC. | $28.99 | 2022 | |
| Organon LLC | $28.92 | 2025 | Nexplanon |
| Exeltis, USA INC. | $21.05 | 2021 | |
| Baxter Healthcare | $19.68 | 2023 | Floseal |
| Biogen, INC. | $18.77 | 2024 | Zurzuvae |
| Mallinckrodt Hospital Products INC. | $17.94 | 2020 | |
| Myovant Sciences INC. | $16.64 | 2022 | |
| Olympus America INC. | $15.24 | 2023 | Olympus |
| Duchesnay USA Incorporated | $14.13 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.50 | 2019 | |
| Scynexis, INC. | $13.20 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.10 | 2021 | |
| Avion Pharmaceuticals | $11.35 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.